Bcl-2-IN-9

Cat. No.:	HY-149009
CAS No.:	2490542-33-9
Molecular Formula:	$C_{27}H_{31}N_7O_3S$
Molecular Weight:	533.65
Target:	Bcl-2 Family; Apoptosis
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

Bcl-2-IN-9 is a novel proapoptotic Bcl-2 inhibitor with IC_{50} value of 2.9 μM and low cytotoxic. Bcl-2-IN-9 mediates apoptosis by down-regulating expression of Bcl-2 in cancer cells and has a high selectivity against leukemia cells[1].

IC_{50} & Target

Bcl-2
2.9 μM (IC_{50}, [1])

In Vitro

Bcl-2-IN-9 (compound 6e) (10 μM, 48 hours) inhibits HL-60 cells in vitro[1].
Bcl-2-IN-9 (compound 6e) (10 μM, 48 hours) shows low cytotoxic effects against WI-38 cells with cell viability of 91%[1].
Bcl-2-IN-9 (compound 6e) (10 μM, 48 hours) displays a high selectivity against leukemia cells[1].
Bcl-2-IN-9 (compound 6e) (10 μM) mediates apoptotic by down-regulating expression of Bcl-2 and causing chromatin compaction and nuclear fragmentation[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line:	HL-60 cells
Concentration:	1, 10, 20, 40 μM
Incubation Time:	48 hours
Result:	Surpressed cell growth and viability to 28.9%.

Cell Cytotoxicity Assay[1]

Cell Line:	WT-38 cells
Concentration:	10 μM
Incubation Time:	48 hours
Result:	Low cytotoxic effects.

Apoptosis Analysis[1]

Cell Line:	HL-60 cells

Concentration:	1, 10, 20, 40 μM
Incubation Time:	48 hours
Result:	Caused chromatin compaction and nuclear fragmentation.

REFERENCES

[1]. Yukari Ono, et al. Design and synthesis of quinoxaline-1,3,4-oxadiazole hybrid derivatives as potent inhibitors of the anti-apoptotic Bcl-2 protein. Bioorg Chem. 2020 Aug; 104: 104245.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA